This is the largest biomarker study of Alzheimer’s disease conducted in Africa to date. The researchers analyzed blood samples from 949 people over age 50 in Nigeria and examined how a large number of proteins were associated with signs of amyloid changes and cognitive impairment. The key findings were then tested in 196 older people in Tanzania and compared with detailed data from a Canadian study. The study is published in the journal Nature Communications.
Similarities and differences in the blood
Several established tau biomarkers showed similar patterns among people with and without likely amyloid pathology in the African and North American groups. The broader protein profile, however, showed some differences and was more similar between the Nigerian and Tanzanian groups than between the African and Canadian groups.
The researchers also found associations between levels of certain proteins and conditions including heart disease, a history of infectious disease, and high cholesterol. Such comorbidities may need to be taken into account when interpreting biomarkers and developing reference values for different parts of the world.
One methodological limitation is that amyloid pathology in the African groups could not be confirmed through brain imaging or cerebrospinal fluid tests. Instead, the researchers used blood p-tau217 and thresholds validated in non-Hispanic white populations, which are unlikely to be optimally suited to the African groups.
Reference: Pola I, Akinyemi T, Tan K, et al. Plasma proteomic profiles of Alzheimer’s disease and neurodegeneration in African cohorts. Nat Commun. 2026;17(1):8215. doi: 10.1038/s41467-026-74971-4
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
